1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Neuland Laboratories Ltd.

Neuland Laboratories Ltd.

18,926.95
INR
-45.40
(-0.24%)
387.97EPS
47.94P/E
238.64BMarket Cap
Nov 10Next Earn
Neuland Laboratories Ltd.
BSE:NEULANDLAB
(Bombay Stock Exchange)

Recent

price

18,926.95

P/E

ratio

47.94

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
607.48
709.05
575.67
587.74
549.22
574.08
507.21
458.1
523.7
576.32
715.65
719.67
904.84
1,181.35
1,118
1,505.95
1,848.6
Revenue per Share
8.09
4.05
17.33
33.83
18.67
30.76
42.01
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
283.71
387.97
Basic EPS, GAAP
36.96
69.54
23.47
46.57
-2.66
28.72
-3.4
-109.66
5.4
6.66
65.44
-29.07
133.35
91.59
86.47
-39.32
- -
Free Cash Flow per Basic Share
- -
- -
- -
1.35
3.12
1.8
1.09
- -
- -
3.86
2
3
5
10
14
12
- -
Dividend per Share
112.68
134.79
124.78
154.75
181.67
562.71
614.14
628.13
545.06
553.36
612.99
655.11
774.83
999.78
1,188.48
1,461.02
- -
Book Value per Share
112.19
134.45
124.28
154.04
180.78
247.56
298.1
311.56
325.83
334.02
392.44
435.64
555.99
780.04
966.88
1,238.32
- -
Tangible Book Value per Share
7
6
8
8
9
9
11
11
13
13
13
13
13
13
13
13
13
Basic Weighted Avg Shares
3,969
4,485
4,606
4,657
4,692
5,100
5,658
5,110
6,592
7,394
9,182
9,233
11,609
15,157
14,344
19,321
23,718
Sales/Revenue/Turnover
8.13
7.37
9.61
12.02
11.15
12.76
15.59
5.87
5.83
9.95
11.94
10.41
20.19
26.88
18.58
25.36
28.03
Operating Margin (%)
154
149
146
149
153
157
192
221
259
313
397
490
528
597
655
917
981
Depreciation Expense
53
26
139
268
159
273
469
121
164
162
806
638
1,635
3,001
2,601
3,640
4,978
Net Income, GAAP
- -
- -
14.84
22.57
35.55
35.53
30.25
13.43
19.16
69.37
23.45
22.32
24.21
25.25
24.9
25.56
25.62
Effective Tax Rate (%)
1.33
0.57
3.01
5.76
3.4
5.36
8.28
2.36
2.49
2.19
8.78
6.91
14.09
19.8
18.13
18.84
20.99
Profit Margin (%)
-606
-665
-357
-193
206
495
894
803
1,265
1,576
1,811
2,176
3,219
4,934
6,738
7,729
- -
Working Capital
716
559
511
339
332
332
298
1,035
607
800
977
1,112
781
541
1,093
2,606
- -
LT Debt
740
765
1,001
1,242
1,616
4,999
5,456
5,580
6,993
7,100
7,865
8,405
9,941
12,827
15,248
18,745
- -
Total Equity
- -
- -
14.07
14.9
10.5
8.32
8.76
3.21
3.44
2.39
8.67
7.17
16.29
24.29
16.5
18.63
- -
Return on Invested Capital (%)
- -
- -
5.07
13.76
8.7
7.47
8.1
2.89
2.71
2.22
9.31
6.95
15.56
24.66
17.28
19.59
- -
Return on Capital (%)
7.45
3.42
15.76
23.95
11.18
8.26
8.97
2.19
2.62
2.3
10.78
7.85
17.83
26.36
18.53
21.42
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
406
- -
LT Borrowings
- -
1,609
- -
LT Finance Leases
- -
997
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
194,889
154,121
238,636

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
14,831
- -
Cash, Cash Equivalents & STI
- -
3,267
- -
Accounts Receivable, Net
- -
5,414
- -
Inventories
- -
5,103
- -
Total Current Liabilities
- -
7,102
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
406
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.5%
19.19%
22.93%
Free Cash Flow
292.34%
-177.1%
-145.48%
Net Income, GAAP
67.5%
49.1%
39.94%
Sales/Revenue/Turnover
15.28%
17.24%
34.7%
Total Cash Common Dividend
- -
48.47%
-14.29%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,396
3,108
3,980
3,284
14,344
2026
2,928
5,143
4,397
7,763
19,321
2027
6,416
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
76.28
25.6
79.18
21.67
202.74
2026
10.83
75.49
31.62
165.76
283.71
2027
115.1
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
14
2026
- -
- -
- -
- -
12
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Neuland Laboratories Limited manufactures active pharmaceutical ingredients, intermediates and peptides for the global pharmaceutical industry from its US FDA, EU GMP and other regulatory-compliant facilities in Telangana, India. The company offers custom manufacturing solutions including process design and development, scale-up from lab to commercial production, analytical method validation, stability studies and regulatory support such as IND, IMPD, NDA and DMF filings; its generic drug services segment supplies approximately 15 mature large-volume APIs encompassing key molecules like Levetiracetam and Mirtazapine across therapeutic areas including anti-diabetics, anti-infectives, anti-hypertensives, neurology and peptides via solid, solution and hybrid manufacturing technologies. Founded in 1984 and headquartered in Hyderabad, Neuland Laboratories operates three primary manufacturing sites in Telangana with additional offices in the United States and Japan, serving customers in over 85 countries primarily in North America, Europe and Japan. Recent developments include board approval in January 2025 for Rs 342 crore capital expenditure to expand peptide synthesizer reactor capacity at Unit-1 from 0.5 KL to 6.37 KL by fiscal 2027 and add 52 KL capacity at Unit-3 within 15-18 months to meet growing demand in its generics drug services and custom manufacturing services businesses; in November 2025, the board greenlit Rs 1.89 billion for a new research and development center at Genome Valley in Hyderabad; the company continues partnerships such as its ongoing supply arrangement for xanomeline with Bristol Myers Squibb following its 2024 acquisition of Karuna Therapeutics, bolstering its custom manufacturing services outlook projected to grow over 50% in coming years.